Bionomics Limited, a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of cancer and diseases of the central nervous system, today announced the initiation of a Phase II clinical study of BNC210, the Company's drug candidate in development for the treatment of anxiety and depression.
from The Medical News http://ift.tt/1FZY24z
Our mission is to advice, and to make the people of the world healthier through the power of information.
No comments:
Post a Comment